IBM
IBM
$232.14
-0.85%
International Business Machines (IBM) is a 115-year-old enterprise technology provider that sells software (Red Hat, watsonx, automation, data and AI platforms), IT consulting and systems integration services, and infrastructure hardware including mainframes and quantum computing systems, operating across 175 countries with roughly 287,000 employees. IBM is best characterized as an incumbent enterprise platform and services integrator rather than a hyperscale disruptor — its moat rests on deep relationships with 95% of the Fortune 500, mission-critical transaction workloads, and a hybrid-cloud narrative built around Red Hat. The current investor debate centers on whether IBM is a credible AI beneficiary or a casualty of it: the stock suffered a roughly 25% single-session collapse in mid-July 2026 after a revenue miss and a lowered forecast, with management and bears pointing to enterprise customers redirecting budgets toward AI-native tools and delayed deal closings. Bulls counter that the HRL Laboratories quantum acquisition, software growth, and a $13.6 billion trailing free cash flow base make the selloff an overreaction, framing IBM as a high-risk, high-reward value-plus-AI optionality story heading into Q3 results.…
IBM
IBM
$232.14
Related headlines
Investment Opinion: Should I buy IBM Today?
Rating: Hold with a speculative-buy tilt for risk-tolerant investors. The core thesis is that IBM's 17.65x forward PE and $13.63 billion trailing free cash flow already discount much of the AI-disruption fear, but the 1.09% Q2 revenue growth means there is no evidence yet of a reacceleration catalyst. The analyst consensus of 'buy' with a mean rating of 2.28 and an average target of $242.65 implies only +4.5% upside, which is thin compensation for the event risk demonstrated by the 37.5% max drawdown.
Supporting evidence is genuinely mixed but leans toward valuation support. On the positive side: forward PE of 17.65x versus trailing 26.07x, a PEG of 0.353, PS of 4.09x near the bottom of a historical 7.6x–16.1x band, gross margin of 58.19%, net margin of 15.68%, trailing FCF of $13.631 billion, and a 2.27% dividend with a sustainable 59.0% payout ratio. On the negative side: revenue growth of 1.09%, operating margin down 294 basis points year-over-year to 15.24%, debt-to-equity of 2.057x, a current ratio of 0.928, and a stock down 20.36% YTD against the S&P 500's +11.93%. The bull and bear data points are roughly balanced, which is precisely why the rating is Hold rather than Buy or Sell.
The biggest risks that could invalidate the thesis are a second consecutive quarter of ~1% revenue growth, further operating margin compression below 15%, and evidence that the HRL quantum bet is too distant to matter. This Hold would upgrade to Buy if Q3 software revenue reaccelerates and forward EPS estimates hold at $12.56, or if the stock pulls back toward the $199–$206 support zone where the risk/reward improves materially. It would downgrade to Sell if revenue growth turns negative or if operating margin falls below 14%, which would call the dividend and buyback capacity into question. Valuation verdict: fairly valued to modestly undervalued on forward earnings and sales multiples relative to IBM's own history, but not cheap enough to compensate for the unresolved growth question — the stock is a value-plus-optionality proposition, not a bargain.
Sign up to view all
IBM 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on IBM's 12-month outlook, with a consensus price target around $242.65 and implied upside of +4.5% versus the current price.
Average Target
$242.65
0 analysts
Implied Upside
+4.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$174 - $297
Analyst target range
Coverage is robust with 23 analysts, and the consensus recommendation is "buy" with a mean rating of 2.28 (where lower is more bullish), indicating a moderately constructive but not euphoric stance. The average target price of $242.65 implies roughly +4.5% upside from the current $232.14, a modest gap that reflects the market's post-crash skepticism and suggests analysts see the stock as fairly valued after the rebound rather than deeply undervalued. The consensus leans mildly bullish — the "buy" label is supported by a cluster of Buy/Overweight ratings from Citigroup, Jefferies, Stifel, Barclays, and RBC — but the presence of Neutral/Market Perform/Equal Weight calls from Susquehanna, BMO, and Morgan Stanley tempers conviction. The full target range of $174 to $297 is wide (a 71% spread from low to high), signaling genuine disagreement about IBM's AI trajectory: the $297 high target assumes software reacceleration, successful quantum/AI optionality from the HRL acquisition, and multiple expansion back toward the pre-crash valuation, while the $174 low target prices in continued revenue stagnation, margin compression from deal delays, and competitive share loss to AI-native tools. Institutional ratings show a stable-to-cautiously-constructive pattern — no downgrades in the visible record, with repeated reaffirmations of Buy/Overweight and Outperform ratings through late July and August 2026 — but the absence of upgrades following the 25% crash suggests analysts are waiting for Q3 evidence that delayed deals close before raising conviction. The wide dispersion and lack of post-crash target revisions imply high uncertainty; investors should treat the $242.65 average as a fair-value anchor rather than a catalyst, with the $174 low as the realistic downside scenario if the revenue deceleration proves structural.
Drowning in data?
Find the real signal!
Bulls vs Bears: IBM Investment Factors
The bear case currently has stronger near-term evidence: revenue growth of 1.09% in Q2 2026, operating margin compression from 18.18% to 15.24% year-over-year, and a 20.36% YTD decline that has left the July gap-down unrepaired. The bull case rests on valuation and cash flow — 17.65x forward earnings, $13.63 billion trailing FCF, a 2.27% dividend, and a PS multiple near the bottom of its historical band — plus analyst consensus that still says 'buy' with a $242.65 average target. The single most important tension is whether the Q2 revenue deceleration is a one-quarter air pocket from delayed deal closings or the start of structural share loss to AI-native platforms; Q3 results that show software reaccelerating toward mid-single digits would validate the bulls, while another ~1% growth quarter would confirm the de-rating is fundamental.
Bullish
- Forward PE of 17.65x looks cheap: IBM trades at 26.07x trailing but only 17.65x forward earnings, a 32% compression that implies the market expects EPS to jump toward the $12.56 consensus FY2026 estimate. For a company with 58.19% gross margins and $13.63 billion of trailing free cash flow, that forward multiple is well below what most large-cap tech names command.
- Free cash flow covers dividend comfortably: Trailing FCF of $13.631 billion against a quarterly dividend bill of roughly $1.59 billion (payout ratio 59.0%, yield 2.27%) leaves substantial room for buybacks, debt paydown, and the $10.464 billion of Q1 acquisitions. Q2 2026 alone generated $2.368 billion of FCF on $2.597 billion operating cash flow.
- Analyst consensus still constructive: All 23 covering analysts carry a 'buy' consensus with a mean rating of 2.28 and an average target of $242.65, implying +4.5% upside from $232.14. The high target of $297 implies roughly 28% upside and reflects a credible path if software growth reaccelerates.
- Valuation near bottom of own band: The PS ratio of 4.09x sits near the low end of a historical range of roughly 7.6x–16.1x, and the PEG of 0.353 is strikingly low relative to expected growth. Either the market is pricing structural deterioration or a value gap exists if Red Hat and watsonx demand recovers.
Bearish
- Revenue growth collapsed to 1.09%: Q2 2026 revenue of $17.162 billion grew just 1.09% year-over-year versus $16.977 billion, a sharp deceleration from +9.5% in Q1 2026 and +12.2% in Q4 2025. This is the direct trigger for the July crash and the core evidence that AI budget reallocation is hitting IBM's core franchises.
- 25% single-session crash, unrepaired gap: The stock fell from $290.23 on July 13 to $217.07 on July 14, 2026, and remains 20.36% lower YTD while the S&P 500 is up 11.93%. The 6-month relative strength of -15.90 versus SPY shows the gap-down has not been recovered, and the 37.5% max drawdown confirms a trend break.
- Operating margin compression: Q2 2026 operating margin of 15.24% fell from 18.18% in Q2 2025, and operating income dropped to $2.615 billion from $3.086 billion despite revenue being roughly flat. Deal delays and mix shift are eroding profitability even as the top line stalls.
- Leverage with thin liquidity cushion: Debt-to-equity of 2.057x and a current ratio of 0.928 mean short-term liabilities exceed current assets, with only $7.217 billion of cash against heavy debt. ROE of 32.45% is flattered by a 4.4x equity multiplier, while ROA of just 5.30% reveals the underlying capital intensity.
IBM Technical Analysis
IBM is in a damaged but stabilizing downtrend: the stock is down 15.88% over the past year and 20.36% year-to-date, a stark underperformance versus the S&P 500's +15.53% and +11.93% over the same windows. At $232.14, the shares sit at roughly 24.8% of the 52-week range of $199.19–$332.46 — in the lower quartile but well off the low, meaning the stock has already absorbed a violent de-rating rather than sitting at fresh lows. The 37.5% max drawdown confirms this was a trend-breaking event, not a routine pullback, and the price is now consolidating in the lower half of its annual band. Recent momentum is bifurcated: the 1-month change of -2.25% lags SPY's +1.22% (relative strength -3.47), yet the 3-month change of +9.16% actually beats SPY's +2.69% (relative strength +6.47), reflecting a sharp post-crash rebound off the July low near $205.77. That divergence — positive 3-month but negative 1-month and deeply negative 1-year — signals a bottoming attempt that has stalled into resistance rather than a confirmed reversal; the 6-month change of -8.42% versus SPY's +7.48% (relative strength -15.90) shows the July gap-down remains unrepaired. Key levels are clear: support at the $199–$206 zone (52-week low and July capitulation low), with secondary support near $219–$220 where the stock has repeatedly found buyers; resistance sits at the $249–$253 area (the September high and the pre-crash April consolidation shelf), with the 52-week high of $332.46 far out of reach. A breakout above $253 would validate the double-bottom and open a path toward $280–$290, while a breakdown below $199 would confirm the downtrend and likely trigger momentum selling. Beta of 0.724 means IBM is roughly 28% less volatile than the market, so position sizing should account for a lower-beta, slower-moving profile — though the 37.5% drawdown proves idiosyncratic event risk can overwhelm that cushion.
Beta
0.72
0.72x market volatility
Max Drawdown
-37.5%
Largest decline past year
52-Week Range
$199-$332
Price range past year
Annual Return
-15.9%
Cumulative gain past year
| Period | IBM Return | S&P 500 |
|---|---|---|
| 1m | -2.3% | +0.2% |
| 3m | +9.2% | +2.9% |
| 6m | -8.4% | +8.4% |
| 1y | -15.9% | +14.9% |
| ytd | -20.4% | +11.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IBM Fundamental Analysis
Revenue growth is anemic but positive: Q2 2026 revenue of $17.162 billion grew just 1.09% year-over-year against $16.977 billion in Q2 2025, and the sequential trend is uneven — $15.917 billion in Q1 2026 (+9.5% YoY vs. $14.541 billion), $19.687 billion in Q4 2025 (+12.2% YoY vs. $17.553 billion), and $16.331 billion in Q3 2025 (+9.1% YoY vs. $14.967 billion). The deceleration to ~1% in the latest quarter is the crux of the bear case and the trigger for the July crash, with the segment mix showing Software at $7.761 billion and Consulting at $5.327 billion as the twin engines, Infrastructure Services at $3.835 billion, and Financing a marginal $186 million. Software and Consulting together represent roughly 76% of segment revenue, so the investment case hinges entirely on whether AI-driven software demand (watsonx, Red Hat) can reaccelerate growth back toward mid-single digits; the consensus FY2026 revenue estimate of $81.47 billion implies only modest recovery. Profitability remains solid and improving at the gross line: Q2 2026 gross margin was 57.73% (gross profit $9.907 billion on $17.162 billion), up from 56.23% in Q1 2026 and 55.23% in Q1 2025, though below the 60.59% peak in Q4 2025. Net income of $2.165 billion in Q2 2026 (net margin 12.62%) compares favorably to $1.216 billion in Q1 2026 (7.64% margin) and $2.194 billion in Q2 2025, while operating margin of 15.24% in Q2 2026 sits below the 18.18% posted in Q2 2025 — evidence of margin compression from deal delays and mix. The company is comfortably profitable with a 15.68% net margin and 18.50% operating margin, but the trajectory is choppy and the Q4 2025 tax benefit (-$1.435 billion tax expense) flattered that quarter's $5.6 billion net income, so investors should anchor on the ~12–13% normalized net margin rather than the headline. Balance sheet and cash flow are the strongest part of the story: trailing free cash flow is $13.631 billion, Q2 2026 FCF was $2.368 billion on $2.597 billion operating cash flow, and Q1 2026 FCF was $4.778 billion — but leverage is elevated with debt-to-equity of 2.057x and a current ratio of 0.928, meaning short-term liabilities exceed current assets. ROE of 32.45% is high but flattered by the 4.4x equity multiplier (thin equity base from buybacks and dividends), while ROA of just 5.30% reveals the underlying capital intensity; the dividend consumes $1.59 billion per quarter (payout ratio 59.0%, yield 2.27%) and Q2 debt repayment of $4.213 billion plus $10.464 billion of Q1 acquisitions show management is actively deploying cash. The company funds growth internally but with limited cushion — FCF covers dividends and capex comfortably, yet the $7.217 billion cash balance against heavy debt and a 0.93 current ratio leaves little room for a prolonged revenue downturn.
Quarterly Revenue
$17.2B
2026-06
Revenue YoY Growth
+1.1%
YoY Comparison
Gross Margin
57.7%
Latest Quarter
Free Cash Flow
$13.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IBM Overvalued?
Because IBM is solidly profitable (Q2 2026 net income of $2.165 billion, TTM EPS positive), the PE ratio is the appropriate primary metric. The stock trades at 26.07x trailing earnings but only 17.65x forward earnings — a 32% compression that implies the market expects meaningful EPS growth, consistent with the consensus FY2026 EPS estimate of $12.56 versus the depressed trailing figure. That forward multiple is the crux of the valuation debate: at 17.65x forward, IBM screens cheap for a technology company, but the gap between trailing and forward PE also signals that the market is skeptical the growth will materialize, given the Q2 revenue deceleration to 1.09%. On a price-to-sales basis, IBM trades at 4.09x (EV/sales 4.02x) and 19.07x EV/EBITDA, while the PEG ratio of 0.353 is strikingly low — suggesting the stock is inexpensive relative to its expected earnings growth rate, though that growth estimate is itself at risk. Peer comparison is constrained by the absence of a supplied industry-average multiple, but contextually IBM's 17.65x forward PE sits at a discount to high-growth software peers and roughly in line with large-cap IT services, while its 4.09x PS is modest for a company with 58.19% gross margins. The premium embedded in the 8.46x price-to-book (versus a historical band that has ranged from roughly 5.4x to 10.0x) reflects the thin equity base rather than rich expectations, and the 20.93x price-to-cash-flow is elevated relative to the 2.27% dividend yield, implying investors are paying for cash generation they expect to grow. Historically, IBM's PE has swung wildly with earnings volatility — 12.4x in Q4 2025, 30.6x in Q2 2026, 46.6x in Q1 2026, and 54.5x in Q1 2025 — so the current 26.07x trailing sits in the middle of that range, while the 17.65x forward is toward the lower end of where the stock has traded on a forward basis. The PS ratio of 4.09x compares to a historical range of roughly 7.6x–16.1x over the past several years, placing the stock near the bottom of its own sales-multiple band — a signal that either the market is pricing in fundamental deterioration (the bear read) or that a value opportunity exists if software growth reaccelerates (the bull read).
PE
26.1x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 11x~47x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
19.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the abrupt revenue stall and its margin consequences. Q2 2026 revenue grew only 1.09% year-over-year, and operating income fell to $2.615 billion from $3.086 billion a year earlier, pushing operating margin down from 18.18% to 15.24%. Leverage adds fragility: debt-to-equity is 2.057x, the current ratio of 0.928 means current liabilities exceed current assets, and the $7.217 billion cash balance offers limited buffer if the revenue downturn persists. The 59.0% dividend payout ratio consumes roughly $1.59 billion per quarter, and while $13.631 billion of trailing FCF covers it comfortably today, a prolonged software slowdown would force a choice between the dividend, buybacks, and the acquisition program that spent $10.464 billion in Q1 alone. Revenue concentration compounds the issue: Software ($7.761 billion) and Consulting ($5.327 billion) are roughly 76% of segment revenue, so the entire thesis hinges on two businesses that are both exposed to enterprise AI budget reallocation.
Market and competitive risks are dominated by the AI narrative and valuation compression. The stock's 37.5% max drawdown and 25% single-session crash show that idiosyncratic event risk overwhelms IBM's low beta of 0.724 — the low correlation to the market did not protect shareholders from a company-specific de-rating. Competitive evidence is mounting: Pegasystems blamed AI-related customer delays for its second consecutive quarterly miss, and coverage comparing IBM unfavorably to Arista and Figma on revenue growth reinforces the perception that IBM is losing share to AI-native platforms. Sector rotation is a further headwind, with recent market commentary noting a rotation from mega-cap tech to value as investors question AI infrastructure ROI — a shift that could help IBM's value profile but also signals that enterprise AI spending is being scrutinized. The wide analyst target range of $174 to $297, a 71% spread, quantifies how genuinely unresolved the competitive question is.
Worst-case scenario: enterprise customers permanently redirect software and consulting budgets to AI-native vendors, Q3 and Q4 revenue growth stays near 1%, forward EPS estimates of $12.56 are cut, and the forward multiple compresses toward the low end of IBM's historical range. In that chain, the stock retests the July capitulation low of $205.77 and then the 52-week low of $199.19 — roughly -14% from the current $232.14. A break below $199 would likely trigger momentum selling toward the analyst low target of $174, which is about -25% from the current price. The 37.5% max drawdown already realized shows that a repeat of the July event from current levels would take the stock into the $145–$150 range, so a realistic adverse-case loss is -14% to -25%, with tail risk closer to -35% if the revenue deceleration proves structural and the dividend comes under scrutiny.
FAQ
The most severe risk is structural revenue stagnation: Q2 2026 growth of 1.09% versus +9.5% in Q1 2026 suggests enterprise AI budget reallocation may be permanently eroding IBM's software and consulting franchises, which together are roughly 76% of segment revenue. Second is margin compression — operating margin fell from 18.18% to 15.24% year-over-year, and further erosion would threaten the 59.0% payout ratio dividend. Third is balance sheet fragility: debt-to-equity of 2.057x, a current ratio of 0.928, and only $7.217 billion of cash leave little cushion for a prolonged downturn. Fourth is event risk — the 25% single-session crash in July 2026 and 37.5% max drawdown show that IBM's low 0.724 beta offers no protection against company-specific shocks.
The 12-month forecast is split three ways: a 50% probability base case of $230–$250, centered on the $242.65 analyst average, assuming revenue stabilizes in the low-to-mid single digits and forward EPS of $12.56 is achieved; a 25% probability bull case of $280–$297, requiring software reacceleration above 5% and operating margin recovery above 17%; and a 25% probability bear case of $174–$199, triggered by another ~1% growth quarter or negative revenue growth that forces EPS estimate cuts. The base case is most likely because the valuation already discounts much of the bad news, but the key assumption — that Q2's deal delays were timing rather than structural — remains unproven until Q3 results.
IBM looks modestly undervalued on forward metrics but fairly valued on near-term earnings power. The trailing PE of 26.07x is unremarkable, but the forward PE of 17.65x represents a 32% compression that prices in meaningful EPS growth toward the $12.56 consensus. The PS ratio of 4.09x sits near the bottom of a historical 7.6x–16.1x band, and the PEG of 0.353 is low relative to expected growth. However, the 8.46x price-to-book is inflated by a thin equity base from buybacks rather than rich expectations, and the 20.93x price-to-cash-flow is elevated against a 2.27% yield. The market is paying a fair price that embeds skepticism about the 1.09% revenue growth turning into something better — if it does, the stock is cheap; if it doesn't, the forward multiple is a value trap.
From a risk/reward perspective, IBM is a reasonable but not compelling buy at $232.14. The stock trades at 17.65x forward earnings and 4.09x sales — cheap for a 58.19% gross-margin technology franchise — and the analyst average target of $242.65 implies only +4.5% upside, so the near-term reward is modest. The biggest downside risk is a retest of the $199.19 52-week low, roughly -14%, or the $174 analyst low, about -25%, if Q3 revenue growth stays near 1%. The 2.27% dividend and $13.63 billion of trailing free cash flow provide a valuation floor that limits catastrophic downside. It is a good buy for patient value and income investors with a 2–3 year horizon who can tolerate event risk, and a poor buy for anyone seeking near-term growth or momentum exposure.
IBM is better suited to long-term holding than short-term trading. Its beta of 0.724 means it moves slowly relative to the market, and the 2.27% dividend with a sustainable 59.0% payout ratio rewards patience, but the 37.5% max drawdown and 25% single-session crash show that short-term event risk is severe and unpredictable. Earnings visibility is moderate — the $12.56 consensus EPS and $81.47 billion revenue estimates are reasonably well-anchored, but the Q2 deceleration introduced genuine uncertainty. A concrete minimum holding period of 18–24 months is appropriate, allowing time for Q3 and Q4 results to resolve the AI disruption question and for the quantum optionality to develop. Short-term traders should avoid the stock until it either breaks above $253 resistance or establishes a confirmed double-bottom above $199.